The Clinical Pharmacology and Analyfical Chemistry (CPAC) Core contains clinical pharmacology expertise with a CLIA-certified laboratory to support clinical and preclinical HIV/AIDS research among CFAR invesfigators at UNC, FHl, and RTI. Since the CPAC Core is the only one of its kind within the CFAR system, it also supports a growing number of invesfigators in other CFARs across the country. The CPAC Core consists of experienced scientists who provide a high level of expertise in trial design, development and validation of analytical methods in complex biological matrices to accurately quantify drug exposure, and interpretation of preclinical and clinical pharmacology data. The CPAC Core also provides leadership in HIV prevention strategies, women's health issues, and international pharmacology, and trains domestic and international investigators in pharmacologic and analytic methods.

Public Health Relevance

A major feature of controlling the HIV epidemic is the complex interplay between drug exposure and response in treatment, prevention, and cure. This is evidenced in the extensive preclinical and early clinical dose-response investigations during drug development. Optimizing effective therapy in any of these areas of the epidemic requires extensive knowledge of exposure targets and pharmacokinefics in multiple body compartments to chose the best doses, dosing frequencies, and drug combinations for efficacy. The CPAC Core provides the necessary resources for CFAR users to optimize their preclinical and clinical research approach.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-ELB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Montgomery, Nathan D; Tomoka, Tamiwe; Krysiak, Robert et al. (2018) Practical Successes in Telepathology Experiences in Africa. Clin Lab Med 38:141-150
Rudolph, Jacqueline E; Cole, Stephen R; Edwards, Jessie K et al. (2018) At-Risk Alcohol Use Among HIV-Positive Patients and the Completion of Patient-Reported Outcomes. AIDS Behav 22:1313-1322
Edwards, Jessie K; Cole, Stephen R; Moore, Richard D et al. (2018) Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. Am J Epidemiol :
Belenky, Nadya; Pence, Brian W; Cole, Stephen R et al. (2018) Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV. Med Care 56:47-53
Bilal, Usama; McCaul, Mary E; Crane, Heidi M et al. (2018) Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. Alcohol Clin Exp Res 42:561-570
Tang, Weiming; Wei, Chongyi; Cao, Bolin et al. (2018) Crowdsourcing to expand HIV testing among men who have sex with men in China: A closed cohort stepped wedge cluster randomized controlled trial. PLoS Med 15:e1002645
Lesko, Catherine R; Edwards, Jessie K; Cole, Stephen R et al. (2018) When to Censor? Am J Epidemiol 187:623-632
Ong, Jason J; Li, Haochu; Dan, Wu et al. (2018) Coercion and HIV Self-Testing in Men Who Have Sex With Men: Implementation Data From a Cross-Sectional Survey in China. J Acquir Immune Defic Syndr 77:e22-e25
Edwards, Jessie K; Cole, Stephen R; Hall, H Irene et al. (2018) Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. AIDS 32:261-266
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647

Showing the most recent 10 out of 1688 publications